Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review

American Journal of Hematology

Volumn 91, Issue 6, 2016, Pages 623-630

  Thejeel, Bashiar ^a,b   Garg, Amit X ^b,c   Clark, William F ^b,c   Liu, Aiden R ^b   Iansavichus, Arthur V ^b   Hildebrand, Ainslie M ^d  

^a WESTERN UNIVERSITY   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DEPRESSION; DISEASE SEVERITY; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; OUTCOME ASSESSMENT; PLASMAPHERESIS; PREECLAMPSIA; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; RISK FACTOR; SEIZURE; SYSTEMATIC REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; COMPLICATION; FOLLOW UP; PLASMA EXCHANGE; QUALITY OF LIFE; THROMBOTIC MICROANGIOPATHIES;

FOLLOW-UP STUDIES; HUMANS; PLASMA EXCHANGE; QUALITY OF LIFE; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME;

EID: 84967138180     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24339     Document Type: Review

References (61)

1. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010;116:4060-4069.
2. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
3. George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: Evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS registry, 1989-2007. Kidney Int Suppl 2009;(112):S52-S54.
4. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. Medicine (Baltimore) 1966;45:139.
5. Remuzzi G. HUS and TTP: Variable expression of a single entity. Kidney Int 1987;32:292-308.
6. Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney Int 1990;38:160-166.
7. Henon P. Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study. Press Med 1991;20:1761-1767.
8. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-397.
9. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: Database of Nara medical university during 1998-2008. Intern Med 2010;49:7-15.
10. Eknoyan G, Riggs SA. Renal involvement in patients with thrombotic thrombocytopenic purpura. Am J Nephrol 1986;6:117-131.
11. Patschan D, Witzke O, Duhrsen U, et al. Acute myocardial infarction in thrombotic microangiopathies-Clinical characteristics, risk factors and outcome. Nephrol Dial Transplant 2006;21:1549-1554.
12. Hawkins BM, Abu-Fadel M, Vesely SK, et al. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: A systematic review. Transfusion 2008;48:382-392.
13. Kennedy AS, Lewis QF, Scott JG, et al. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009;49:1092-1101.
14. Tsai HM. The kidney in thrombotic thrombocytopenic purpura. Miner Med 2007;98:731-747.
15. Vesely SK, Li X, McMinn JR, et al. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004;44:1149-1158.
16. Viswanathan S, Rovin BH, Shidham GB, et al. Long-term, sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura. Br J Haematol 2010;149:623-625.
17. Cataland SR, Scully MA, Paskavitz J, et al. Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol 2011;86:87-89.
18. Dierkes F, Andriopoulos N, Sucker C, et al. Indicators of acute and persistent renal damage in adult thrombotic microangiopathy. PLoS One 2012;7:e30886.
19. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009;62:1006-1012.
20. Clark WF. Thrombotic microangiopathy: Current knowledge and outcomes with plasma exchange. Semin Dial 2012;25:214-219.
21. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: An update from the Canadian apheresis group. Ann Intern Med 1999;131:453-462.
22. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: The sixth special issue. J Clin Apher 2013;28:145-284.
23. Lewis QF, Lanneau MS, Mathias SD, et al. Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009;49:118-124.
24. Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 2013;122:2023-2029.
25. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-437.
26. Ascari E, Bobbio-Pallavicini E, Adami R, et al. Thrombotic thrombocytopenic purpura (TTP) treatment: Italian cooperative retrospective study on 29 cases. Haematologica 1986;71:39-43.
27. Falter T, Alber KJ, Scharrer I. Long term outcome and sequelae in patients after acute thrombotic thrombocytopenic purpura episodes. Hamostaseologie 2013;33:113-120.
28. Breckenridge RL, Jr, Solberg LA, Pineda AA, et al. Treatment of thrombotic thrombocytopenic purpura with plasma exchange, antiplatelet agents, corticosteroid, and plasma infusion: Mayo clinic experience. J Clin Apher 1982;1:6-13.
29. Blitzer JB, Granfortuna JM, Gottlieb AJ, et al. Thrombotic thrombocytopenic purpura: Treatment with plasmapheresis. Am J Hematol 1987;24:329-339.
30. Douzinas EE, Markakis K, Karabinis A, et al. Early plasmapheresis in patients with thrombotic thrombocytopenic purpura. Crit Care Med 1992;20:57-61.
31. Hayward CP, Sutton DM, Carter WH, Jr., et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med 1994;154:982-987.
32. Blanco A, Palacio C, Lopez A, et al. Thrombocytopenic thrombotic purpura. Retrospective study of 22 consecutive occurrences in 16 patients. Med Clin (Barc) 1998;111:385-388.
33. Dervenoulas J, Tsirigotis P, Bollas G, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol 2000;79:66-72.
34. Christidou F, Athanasiadou A, Kalogiannidis P, et al. Therapeutic plasma exchange in patients with grade 2-3 hematopoietic stem cell transplantation-associated thrombotic thrombocytopenic purpura: A ten-year experience. Ther Apher Dial 2003;7:259-262.
35. Ziman A, Mitri M, Klapper E, et al. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: One institution's experience and review of the literature. Transfusion 2005;45:41-49.
36. Outschoorn UM, Ferber A. Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: A retrospective cohort study. Am J Hematol 2006;81:895-900.
37. Tuncer HH, Oster RA, Huang ST, et al. Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: A single-institution experience. Transfusion 2007;47:107-114.
38. Ozkalemkas F, Ali R, Ozkocaman V, et al. Therapeutic plasma exchange plus corticosteroid for the treatment of the thrombotic thrombocytopenic purpura: A single institutional experience in the southern Marmara region of Turkey. Transfus Apher Sci 2007; 36:109-115.
39. Basic-Jukic N, Kes P, Bubic-Filipi L, Brunetta B. Treatment of thrombotic microangiopathies with plasma exchange. Hematology 2007;12:63-67.
40. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007;109:2815-2822.
41. Federici L, Klouche K, Amigues L, et al. Outcome and prognosis of severe thrombotic microangiopathies treated by plasma exchange. Med Sci Monit 2006;12:CR302-CR307.
42. Zeitler H, Ulrich-Merzenich G, Walger P, et al. Treatment of adults with clinically suspected severe thrombotic thrombocytopenic purpura-Experiences of a single centre. Transfus Med Hemother 2007;34:64.
43. Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008;141:651-658.
44. Forzley BR, Sontrop JM, Macnab JJ, et al. Treating TTP/HUS with plasma exchange: A single centre's 25-year experience. Br J Haematol 2008;143:100-106.
45. Jasti S, Coyle T, Gentile T, et al. Rituximab as an adjunct to plasma exchange in TTP: A report of 12 cases and review of literature. J Clin Apher 2008;23:151-156.
46. Zhan H, Streiff MB, King KE, et al. Thrombotic thrombocytopenic purpura at the Johns Hopkins hospital from 1992 to 2008: Clinical outcomes and risk factors for relapse. Transfusion 2010;50:868-874.
47. de la Rubia J, Moscardo F, Gomez MJ, et al. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study. Transfus Apher Sci 2010;43:299-303.
48. Chemnitz JM, Uener J, Hallek M, et al. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 2010;89:1029-1033.
49. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011;118:1746-1753.
50. El-Husseiny NM, Goubran H, Fahmy HM, et al. Postgrad Med J 2012;88:433-436.
51. Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French thrombotic microangiopathies reference center. Crit Care Med 2012;40:104-111.
52. Westwood JP, Webster H, McGuckin S, et al. Rituximab for thrombotic thrombocytopenic purpura: Benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013;11:481-490.
53. Goyal J, Adamski J, Lima JL, Marques MB. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab. J Clin Apher 2013;28:390-394.
54. Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010;115:1500-1511.
55. Reese JA, Muthurajah DS, Kremer Hovinga JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 2013;60:1676-1682.
56. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008;3:249-277.
57. Gandhi C, Khan MM, Lentz SR, Chauhan AK. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood 2012;119:2385-2391.
58. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:654-666.
59. Cataland SR, Wu HM. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Clinically differentiating the thrombotic microangiopathies. Eur J Intern Med 2013;24:486-491.
60. Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol 2014;164:759-766.
61. Rosove MH. Thrombotic microangiopathies. Semin Arthritis Rheum 2014;43:797-805.